We Write Code Adopts WWC as Public-Facing Name, Reorganizes Around Six Services and Puts AI at the Center Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Segra International Announces Development and Validation of In-House Assay for Hop Latent Viroid (HLVd)
VANCOUVER, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Segra International Corp, a leading cannabis…
Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN…
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
-AGTC will highlight the value of the patient voice in gene therapy development- GAINESVILLE, Fla….
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with…
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over…
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently…
Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology…
Yield10 Bioscience to Present at the Benzinga Biotech Small Cap Conference on March 25, 2021
WOBURN, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural…
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
Israel Institute for Biological Research (IIBR) reports successful challenge studies using human ACE2 transgenic mice…
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting
Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world…
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) — APIE Therapeutics, a preclinical biopharma company pioneering…
Eyenovia to Report Fourth Quarter and Full Year 2020 Results on Thursday, March 25
Company to host an investor conference call and webcast at 4:30pm ET on that day…
ORYZON to Participate in Upcoming Virtual International Conferences in March and April
BIO-Europe Spring 2021 Kempen Life Sciences Conference 4th SACHS Annual Neuroscience Innovation Forum 2021 MADRID,…
Celularity Announces Fast Track Designation by the FDA for its Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology…
Foghorn Therapeutics Provides Corporate Update
– FHD-286 Phase 1 data anticipated as early as year-end 2021 – FHD-609 IND submission…
Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical…
ADMA Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021
Conference Call Scheduled for March 25, 2021 at 4:30 p.m. ET RAMSEY, N.J. and BOCA…
Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020
‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒‒ Final Data, Including Bone…